16014677

Source:http://linkedlifedata.com/resource/pubmed/id/16014677

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0026336, umls-concept:C0030705, umls-concept:C0038013, umls-concept:C0205177, umls-concept:C0439234, umls-concept:C0666743, umls-concept:C0717758, umls-concept:C1707455, umls-concept:C1947933
pubmed:issue	2
pubmed:dateCreated	2006-1-13
pubmed:abstractText	To estimate the incremental cost-utility of etanercept and infliximab compared with usual care in active ankylosing spondylitis.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-10109801, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-10172868, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-10515650, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-10874387, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-11053096, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-11469469, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-11762956, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-11890649, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-11920412, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-11955536, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-11959767, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-11986408, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-12022358, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-12382292, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-12784417, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-12794835, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-12860728, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-12860729, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-12905476, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-12922951, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-12922952, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-12922954, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-14613288, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-15082483, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-15226514, http://linkedlifedata.com/resource/pubmed/commentcorrection/16014677-15367247
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0372355
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor, http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein, http://linkedlifedata.com/resource/pubmed/chemical/infliximab
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0003-4967
pubmed:author	pubmed-author:BoendermakerAA, pubmed-author:BoonenAA, pubmed-author:BrandtJJ, pubmed-author:BraunJJ, pubmed-author:LandewéRR, pubmed-author:SeverensJ LJL, pubmed-author:SieperJJ, pubmed-author:van der HeijdeDD, pubmed-author:van der LindenSjS
pubmed:issnType	Print
pubmed:volume	65
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	201-8
pubmed:dateRevised	2009-11-18
pubmed:meshHeading	pubmed-meshheading:16014677-Acute Disease, pubmed-meshheading:16014677-Adult, pubmed-meshheading:16014677-Antibodies, Monoclonal, pubmed-meshheading:16014677-Antirheumatic Agents, pubmed-meshheading:16014677-Cohort Studies, pubmed-meshheading:16014677-Drug Costs, pubmed-meshheading:16014677-Female, pubmed-meshheading:16014677-Humans, pubmed-meshheading:16014677-Immunoglobulin G, pubmed-meshheading:16014677-Male, pubmed-meshheading:16014677-Markov Chains, pubmed-meshheading:16014677-Middle Aged, pubmed-meshheading:16014677-Models, Economic, pubmed-meshheading:16014677-Patient Acceptance of Health Care, pubmed-meshheading:16014677-Physician's Practice Patterns, pubmed-meshheading:16014677-Quality-Adjusted Life Years, pubmed-meshheading:16014677-Randomized Controlled Trials as Topic, pubmed-meshheading:16014677-Receptors, Tumor Necrosis Factor, pubmed-meshheading:16014677-Spondylitis, Ankylosing, pubmed-meshheading:16014677-Time Factors, pubmed-meshheading:16014677-Treatment Outcome
pubmed:year	2006
pubmed:articleTitle	Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
pubmed:affiliation	Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, Netherlands. aboo@sint.azm.nl
pubmed:publicationType	Journal Article